TOP

Luohe Chief Pharmaceutical Co., Ltd

  Chief Pharma, Bring Good Health to Mankind


     Ambition, Capability, Accountability, Responsibility



Founded in 2013, Chief Pharma is a high-tech enterprise, focusing on the research and development, production and sales of active pharmaceutical ingredients (APIs) and intermediates. We're featured with Rifamycin series products, specializing in the production of Rifamycin S, Rifampicin, Rifaximin, Rifabutin, Rifamycin Sodium and other products in a large scale. USDMFs and CEPs for Rifamycin series products have already been submitted, and registration in Europe, USA and other countries and regions has been completed.

 

Our headquarter is located in Luohe City, Henan Province, the hinterland of the central plains. We're committed to the research, development and production of APIs and intermediates in the field of anti-tuberculosis, anti-virus, cardiovascular and diabetes, as well as enzyme production technology in commercial production.

 

We always keep in mind that quality is the cornerstone of the survival, and that's why customers choose us. We strictly abide by the quality control, and offer reliable products to customers.

 

With ambition, capability, accountability and responsibility, we'll stay true to original aspiration, forge ahead and together build a bright future of Chief Pharma!


  • 2013 Founded
  • 150 Employees
  • 70000+ Factory Area(㎡)
  • 1200+ Laboratory Area(㎡)

Company History

Sep 2013

The company was registered and founded in Luohe, Henan

Mar 2016

The factory was built in Yancheng District, Luohe City

Dec 2017

Enzyme pilot plant was established

Dec 2018

Enzyme fermentation plant was built

Oct 2019

Enzymatic reaction plant, Enzymatic products refine plant were established

Dec 2019

R&D, trial production of Rifamycin Sodium, Rifabutin, Rifaximin, Sodium Aminosalicylate, Rifamycin S were completed

Oct 2020

The QC laboratory and QA system began to operate

Dec 2020

Synthesis plants of Rifabutin, Rifaximin, Sodium Aminosalicylate, Rifamycin Sodium, Rifamycin S were completed

Jan 2021

Site audit for Drug Manufacturing License from NMPA

Jan 2021

Pilot production of Rifabutin, Rifaximin, Sodium Aminosalicylate, Rifamycin Sodium & Rifamycin S was completed

Feb 2021

Process Validation for Rifabutin, Rifaximin, Sodium Aminosalicylate, Rifamycin Sodium, and Rifamycin S was started

April 2021

Submission of USDMFs and CEPs for Rifabutin, Rifaximin, Rifamycin Sodium, Rifamycin S was began

July 2021

USDMF submission for Rifamycin S was completed

Sep-Nov 2021

WC for Rifaximin and Rifamycin Sodium were obtained

May 2022

WC for Rifabutin was obtained

Production Environment

Corporate Culture

  • Target

    Bring good health to mankind
  • Responsibility

    Keep the bottom line of safety, protect the rights and interests of employees and maintain the ecological environment
  • Philosophy

    Be reliable pharmaceutical enterprise, Be moral to mankind

Accreditation